Is earlier better? Current questions on why, when and how to treat non-metastatic castration-resistant prostate cancer

Learning objectives:

After participating in this broadcasts, you should be able to:
- Discuss the need for and the clinical benefits of earlier treatment in patients with castration-resistant prostate cancer (CRPC)
- Define the clinical impact of delaying metastases in prostate cancer
- Review the current clinical treatment options and management in non-metastatic castration-resistant prostate cancer (nmCRPC)

Scientific Committee:

- Eleni Efstathiou
- Fred Saad

Faculty:

- Boris Hadaschik
- Miguel Mamírez-Backhaus